scholarly journals TRANS VESICAL PROSTATECTOMY

2010 ◽  
Vol 17 (04) ◽  
pp. 578-580
Author(s):  
NISAR AHMED ◽  
MASUD MALIK ◽  
ABDUL RASHEED ◽  
Malik Hussain ◽  
Muhammad Iqbal ◽  
...  

To determine the effectiveness of prostectomy in reducing symptom severity and quality of life. Design: A prospective study. Setting: Urology department civil hospital Dadu. Period: 2005 to 2007. Patients & methods: 100 men under going prostectomy were assessed using the American urological Association (AUA) symptom index score and quality of life. The adverse events like urinary incontinence, erectile dysfunction and retrograde ejaculation also detected. The outcome was assessed after 3 month of prostectomy. Results:Prostectomy was effective in reducing symptoms. Initial mean IPSS was 25 and reduced to 7 with p value < 0.001. Quality of life also assessed which showed majority of cases were mostly satisfied. Adverse events like transient incontinence 10%, retrograde ejaculation in 65% and erectile dysfunction in 25% respectively. Conclusion: Prostectomy is effective in reducing symptom severity and improve quality of life whichwas detected by IPSS and quality of life questionnaire.

2013 ◽  
Vol 88 (4) ◽  
pp. 670-671 ◽  
Author(s):  
Catiussa Spode Brutti ◽  
Renan Rangel Bonamigo ◽  
Taciana Cappelletti ◽  
Gabriela Mynarski Martins-Costa ◽  
Ana Paula Salin Menegat

Attempted to evaluate and compare the impact on quality of life of occupational and non-occupational ACD and to identify the most frequently involved allergens. A quality of life questionnaire was applied. We noted moderate impact on the quality of life of both groups, without a statistical difference. Our study corroborates previous general data on the prevalence of nickel sulphate and paraphenylenediamine as the most common allergens. Potassium bichromate was shown to be one of the main occupational allergens and thimerosal as the main non-occupational allergen in our sample.


2020 ◽  
Vol 19 ◽  
pp. 153473542094328
Author(s):  
Ester Oneda ◽  
Fausto Meriggi ◽  
Laura Zanotti ◽  
Elisabetta Zaina ◽  
Sara Bighè ◽  
...  

Background: Chemotherapy-induced peripheral neuropathy (CIPN) is an adverse event of taxanes, with no effective prevention or treatment available and a highly negative impact on patient quality of life. The aim of this study is to asses that the constant application of cooled cuffs on the hands and feet prevent and mitigate CIPN. Methods: Patients with breast, gynecologic, and pancreatic cancer who received weekly paclitaxel (PTX), PTX/carboplatin, and nab-paclitaxel (nab-PTX)/gemcitabine for any indication at the therapeutic scheduled dosage were included in this prospective study. Hilotherm Chemo care device forms a closed-loop system with cuffs and tubes through which a coolant flows at a temperature of 10 °C. CIPN was monitored using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (edition 3.0), and the tolerability and side effects were scored by using the Common Terminology Criteria for Adverse Events (T4.03 2017). Results: To date, we have enrolled 64 patients. Of these, 54 (84%) completed all cooling cycles. Continuous cooling was well tolerated by all patients. No patients had grade >2 CIPN or had serious or lasting adverse events as a result of Hilotherapy. The median time to CIPN onset was 77 days for the entire population. Conclusion: Hilotherapy has good effectiveness and tolerability and seems to be able to prevent or reduce the symptoms of CIPN. We are still recruiting patients to obtain more data and to collect data at 3 months after the end of chemotherapy. Prospective studies seem to be warranted.


2019 ◽  
Vol 160 (6) ◽  
pp. 1118-1123 ◽  
Author(s):  
Grant S. Gillman ◽  
Giuseppe V. Staltari ◽  
Yue-Fang Chang ◽  
Jose L. Mattos

Objective Examine outcomes of septoplasty with turbinate reductions in patients with allergic rhinitis as compared to patients without allergic rhinitis using validated outcome and quality-of-life (QOL) instruments. Study Design Prospective observational cohort study. Setting Single surgeon, university hospital. Subjects and Methods Consecutive study-eligible patients with a symptomatic nasal septal deviation, with (n = 30) or without (n = 30) documented allergic rhinitis, were enrolled from March 2014 to February 2017. All patients subsequently underwent nasal septoplasty and inferior turbinate reductions. Outcomes were studied using the Nasal Obstruction Symptom Evaluation (NOSE) scale, mini–Rhinoconjunctivitis Quality of Life Questionnaire (mini-RQLQ), and Ease-of-Breathing (EOB) Likert scores completed preoperatively and, together with a patient satisfaction Likert, at 3 and 6 months postoperatively. Results NOSE scores, EOB scores, and mini-RQLQ scores improved significantly in both groups at 3 and 6 months postoperatively. Results were sustained from 3 to 6 months. Although mini-RQLQ scores in allergic patients were higher at all intervals, the magnitude of change in scores in both groups was comparable. Conclusion Although patients with allergic rhinitis report greater allergy-related QOL impairment (mini-RQLQ) on a day-to-day basis than nonallergic patients, this does not appear to attenuate the benefit they might experience from septoplasty and turbinate reductions when indicated for nasal obstruction. Furthermore, the symptomatic relief of their structural nasal obstruction appears to significantly improve their overall allergy-related quality of life. If appropriate expectations are set pre-operatively, allergic rhinitis is neither a contraindication nor a deterrent to septoplasty and turbinate reductions and these patients can reasonably expect a high degree of satisfaction post-operatively.


2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Mary S. Morris ◽  
Amanda Lowery ◽  
Demetrios S. Theodoropoulos ◽  
R. Daniel Duquette ◽  
David L. Morris

Due to its excellent safety profile, ease of administration, and economic considerations, sublingual immunotherapy (SLIT) is becoming a preferred form of allergen specific immunotherapy. The efficacy of SLIT is still debated. The purpose of this act of practice trial is to evaluate quality of life outcomes in patients treated with SLIT. Fifty one patients with allergic rhinoconjunctivitis demonstrated by skin testing completed the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) at initiation, at four months and at 10–12 months of SLIT. Significant improvement () on six of seven domain categories of the RQLQ questionnaire was noted. Total RQLQ scores also showed significant improvement. This study supports SLIT as a modality effective in controlling allergic symptoms.


2021 ◽  
Author(s):  
Samuel Opoku Asiedu ◽  
Alexander Kwarteng ◽  
Emmanuel Kobla Atsu Amewu ◽  
Priscilla Kini ◽  
Bill Clinton Aglomasa ◽  
...  

Abstract BackgroundHuman lymphatic filarial pathology is the leading cause of disability and poverty among people living with the infection. The second goal of the Global Programme to Eliminate Lymphatic Filariasis (GPELF) is to manage the disease's morbidity to improve patients' quality of life. Consequently, the current study assessed the overall quality of life of lymphatic filariasis (LF) pathology patients in some selected endemic communities in rural Ghana. MethodIn the present study, the Lymphatic Filariasis Quality of Life Questionnaire (LFSQQ) was used to evaluate the effect of lymphatic filariasis on the quality of life of people, with the disease in nine (9) communities in the Ahanta West District of the Western Region of Ghana where mass drug administration is being implemented for the past twenty years. Pearson’s correlation, linear regression, and one-way analysis of variance (ANOVA) analyses were used to assess the associations between the LFSQQ instrument domains.ResultsOf the 155 study participants recruited, 115 (74.19%) were females, and 40 (25.81%) males. A greater proportion of the study participants (40, 25.8%) were presented with stage two (2) lymphoedema, while only two patients had stage seven (7) lymphoedema. The average of the overall quality of life scores of study participants was 68.24. There was a negative Pearson correlation (r = -0.504, p-value < 0.001) between the stage of lymphoedema (severity of the disease) and the quality of life of the LF patients. In addition, a clear pattern of positive correlation (r = 0.71, p-value < 0.001) was observed between the disease burden and pain/discomfort domains of the study participants. Whereas the highest domain-specific score (85.03) was observed in the domain of self-care, we noted that the environmental domain, which consists of the financial status, was the lowest (45.94) among the study participants. ConclusionOur findings support previous works on the reduced quality of life among lymphatic filariasis patients with pathology. In this study, our results reveal a depressing financial condition among people presenting with late stages of LF pathologies, which eventually reduces their well-being.


2017 ◽  
Vol 35 (4) ◽  
pp. 373
Author(s):  
Sophit Korpunsilp ◽  
Tipaporn Pongmesa

Objective: To assess quality of life (QoL) of female breast cancer patients undergoing chemotherapy with a fluorouracil, doxorubicin, and cyclophosphamide (FAC) regimen.Material and Method: This prospective analytical study was performed among 40 Thai female patients receiving the FAC regimen at Pranangklao Hospital, Nonthaburi province. Their QoL was assessed using the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and Breast Cancer Module (EORTC QLQ-BR23).Results: Most patients were aged 50 years or over (77.5%) and had been diagnosed with stage 2 breast cancer (47.5%). According to the EORTC QLQ-C30, the patients’ QoL significantly decreased compared to the baseline after cycle 3 for global health status (p-value=0.002) and QoL (p-value=0.001), as well as physical functioning (p-value=0.015) and role functioning (p-value=0.001), while symptoms of fatigue, nausea/vomiting, and appetite loss increased (p-value<0.001). After cycle 5, the patients’ QoL was still significantly lower than at baseline, for physical functioning (p-value=0.009) and symptoms of fatigue, nausea/vomiting, appetite loss (p-value<0.001) and dyspnea (p-value=0.005). The EORTC QLQ-BR23 reported significantly worse systemic therapy side effects for both cycles 3 and 5 (p-value<0.001), and distress due to hair loss also appeared after cycle 5 (p-value=0.016). No significant differences were revealed on any scales between cycles 3 and 5.Conclusion: The patients’ QoL significantly decreased after chemotherapy with the FAC regimen, with some side effects from treatment and reduction in some functioning.


2015 ◽  
Vol 81 (7) ◽  
pp. 738-746 ◽  
Author(s):  
Sheri A. Mancini ◽  
Jillian L. Angelo ◽  
Zachary Peckler ◽  
Frances H. Philp ◽  
Katie F. Farah

Gastroparesis is a chronic gastric motility disorder in which the pathophysiology mimics a post-vagotomy state. Pyloroplasty is beginning to emerge as a successful drainage procedure for refractory gastroparesis. Here we report our experience using pyloroplasty in the surgical management of diabetic and nondiabetic gastroparesis. A retrospective study was performed of 46 patients undergoing pyloroplasty for refractory gastroparesis from January 2010 through December 2013. Gastric emptying scintigraphy and the Gastroparesis Cardinal Symptom Index were assessed pre-and postoperatively. Laparoscopic pyloroplasty was performed in 42 patients, open pyloroplasty in three, and one patient was converted from laparoscopic to open pyloroplasty. Studies were repeated during the six to 12 month postoperative interval. The postoperative gastric emptying scintigraphy improved in 90 per cent of patients and normalized in 60 per cent. Postoperative T½ was significantly reduced ( P = 0.001) as was four-hour retention ( P < 0.001). The Gastroparesis Cardinal Symptom Index showed statistically significant reduction in symptom severity for all nine categories ( P < 0.0005) as well as total symptom score ( P < 0.005). No patients developed dumping syndrome. Pyloroplasty is a highly effective therapy for refractory gastroparesis, offering significant reduction in symptom severity, improvement in quality of life, and acceleration of gastric emptying.


2020 ◽  
Vol 91 (4) ◽  
pp. 251-255 ◽  
Author(s):  
Mattia Sibona ◽  
Paolo Destefanis ◽  
Marco Agnello ◽  
Beatrice Lillaz ◽  
Mattia Giuliano ◽  
...  

Objectives: Chronic prostatitis syndrome is a bothering and poorly understood condition. Many patients report genitourinary pain and Lower Urinary Tract Symptoms as a main complaint. Many different pharmacological or behavioural therapies are prescribed in daily clinical practice, but efficacy data are still lacking. The aim of our study was to test the efficacy and safety of a transrectal delivered association of Boswellia resin extract and propolis derived polyphenols for the relief of prostatitis - like symptoms. Materials and methods: Patients affected by chronic/recurrent prostatitis - like symptoms were prospectively enrolled in our study from December, 2016 to December, 2018. Patients were screened at baseline through clinical examination and validated questionnaires administration: Chronic Prostatitis Symptom Index (CPSI), International Prostate Symptom Score (IPSS), International Index of Erectile Function (IIEF). Inclusion criteria were: age ≥ 18; prostatitis symptoms persisting for at least 3 of the last 6 months; CPSI pain domain score ≥ 5; previous negative Meares-Stamey test. Treatment consisted on the administration of 1 suppository containing Boswellia resin extract and propolis derived polyphenols, once a day for 20 days. The primary endpoint of the study was the improvement of quality of life after treatment, defined by a reduction of ≥ 2 points, or ≥ 25%, of mean CPSI pain domain score, compared to baseline. Secondary endpoints were the improvement of post-treatment CPSI total score and the analysis of treatment - related adverse events. All patients were re-evaluated 1 month after treatment. Results: 40 patients were enrolled in our study. Median age (Inter - Quartile Range IQR) was 51.5 (41.5-63.2) years. Mean baseline CPSI scores were: 22.15 (total score), 9.67 (pain domain), 5.15 (micturition domain) and 7.35 (quality of life domain), respectively. No significant adverse events were reported. At 1 month follow-up, CPSI scores appeared modified as follows: 16.40 (total score, p = 0.001); 6.92 (pain domain; p = 0.001; 4.02 (micturition domain, p = 0.09); 5.45 (quality of life domain, p = 0.002). Mean CPSI pain domain score reduction was -2.75 points (-28.5%). Mean CPSI total score reduction was -5.75 points (-26%). Conclusions: The association of Boswellia resin extract and propolis derived polyphenols can reduce genitourinary pain and then improve quality of life of men affected by bothersome prostatitis - like symptoms.


Sign in / Sign up

Export Citation Format

Share Document